

Full-year 2023 *results*



• 2023 was a turning-point year for Sanofi, paving the way for our scientific leadership in Immunology. Coupled with our AI at-scale ambitions, we go forward as a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. •

Paul Hudson
Chief Executive Officer, Sanofi

Company sales and business EPS*

€43,070m

+5.3% (+0.2%)

Full-year 2023
company sales **



Layla Bral, Associate Scientist,
Ghent, Belgium

€8.11

+5.4% (-1.8%)

Full-year 2023
business EPS **

* Earnings per share

** Growth rates are expressed at constant exchange rates (CER).
Growth rates in parentheses are expressed on a reported basis.

Sales by global business unit




€18,040m

Specialty Care




€12,376m

General Medicines



T cell, close-up in 3D



€7,474m

Vaccines



€5,180m

Consumer Healthcare

Sales by geography

US

€18,512m

Europe

€10,392m



Charly Toral, Laboratory Technician,
Val de Reuil, France

Rest of World

€14,166m

Research & Development highlights

Advancing breakthrough science



Record

12

blockbuster opportunities
under clinical evaluation



More than

35

Phase 3 projects
by 2025

For further information on full-year 2023 results and definitions of financial indicators, please refer to the press release issued on February 1, 2024 at: www.sanofi.com/en/investors

sanofi



@Sanofi



@Sanofi



@Sanofi



@Sanofi